Williams & Novak LLC Purchases 14,000 Shares of Accuray Incorporated $ARAY

Williams & Novak LLC raised its position in shares of Accuray Incorporated (NASDAQ:ARAY) by 25.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 68,970 shares of the medical equipment provider’s stock after acquiring an additional 14,000 shares during the period. Williams & Novak LLC owned approximately 0.07% of Accuray worth $94,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Nuveen LLC acquired a new position in shares of Accuray during the first quarter valued at about $609,000. Hsbc Holdings PLC raised its position in shares of Accuray by 15.4% during the first quarter. Hsbc Holdings PLC now owns 122,654 shares of the medical equipment provider’s stock valued at $221,000 after buying an additional 16,389 shares during the last quarter. Bank of America Corp DE raised its position in shares of Accuray by 102.7% during the fourth quarter. Bank of America Corp DE now owns 146,803 shares of the medical equipment provider’s stock valued at $291,000 after buying an additional 74,394 shares during the last quarter. Armistice Capital LLC raised its position in shares of Accuray by 105.2% during the first quarter. Armistice Capital LLC now owns 2,536,000 shares of the medical equipment provider’s stock valued at $4,539,000 after buying an additional 1,300,000 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new position in shares of Accuray during the fourth quarter valued at about $144,000. 64.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ARAY. Wall Street Zen raised shares of Accuray from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. BTIG Research upped their price objective on shares of Accuray from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Thursday, August 14th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Accuray in a research report on Wednesday. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Accuray currently has an average rating of “Hold” and an average target price of $5.00.

Accuray Stock Performance

NASDAQ:ARAY opened at $1.77 on Friday. Accuray Incorporated has a 12-month low of $1.14 and a 12-month high of $2.95. The company has a quick ratio of 0.92, a current ratio of 1.65 and a debt-to-equity ratio of 1.53. The firm has a market capitalization of $199.51 million, a PE ratio of -88.50 and a beta of 1.31. The firm has a 50-day moving average price of $1.57 and a 200 day moving average price of $1.50.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings results on Wednesday, August 13th. The medical equipment provider reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). The business had revenue of $127.54 million during the quarter, compared to analyst estimates of $123.78 million. Accuray had a negative return on equity of 4.92% and a negative net margin of 0.35%. Accuray has set its FY 2026 guidance at EPS. Research analysts anticipate that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.